ArticleEvidence-based complementary and alternative medicine : eCAM2017
Liensinine and Nuciferine, Bioactive Components of
Article in Evidence-based complementary and alternative medicine : eCAM, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 53 citations in OpenAlex.
- Liensinine-loaded extracellular vesicles mitigate osteoporosis through inhibition of NF-κB signaling and calcium oscillations in osteoclasts.Molecular and cellular biochemistry · 2026Article
- Insights into nuciferine: A natural multifunctional bioactive alkaloid (Review).Molecular medicine reports · 2026Review
- Molecular Mechanisms Underlying the Anti-Tumor Activity of Lotus-Derived Alkaloids in Breast Cancer.Molecules (Basel, Switzerland) · 2026Article
- Antiproliferative Activity Screening inACS omega · 2025Article
- Lotusin A: a novel pyrrole terpenoid hydrid from lotus roots (RSC advances · 2025Article
- Pharmacological Potential and Mechanisms of Bisbenzylisoquinoline Alkaloids from Lotus Seed Embryos.Biomolecules · 2025Review
- The antineoplastic effects of nuciferine on hepatocellular carcinoma are associated with suppression of the HER2-AKT/ERK1/2 signaling pathway.Discover oncology · 2025Article
- Preparation, pharmacokinetics and anti-obesity effects on dogs of nuciferine liposomes.Veterinary medicine and science · 2024Article
- Article
- Small-molecule amines: a big role in the regulation of bone homeostasis.Bone research · 2023Review
- Functional characterization and key residues engineering of a regiopromiscuityHorticulture research · 2023Article
- Preventive Effect of Nuciferine on HMolecules (Basel, Switzerland) · 2022Article
- Lotus (Cancers · 2022Review
- Liensinine Inhibits Cell Growth and Blocks Autophagic Flux in Nonsmall-Cell Lung Cancer.Journal of oncology · 2022Article
- Lotus leaf extract inhibits ERNutrition & metabolism · 2021Article
- Update and New Insights on Future Cancer Drug Candidates From Plant-Based Alkaloids.Frontiers in pharmacology · 2021Review
- TCPP-Isoliensinine Nanoparticles for Mild-Temperature Photothermal Therapy.International journal of nanomedicine · 2021Article
- Nuciferine Inhibited the Differentiation and Lipid Accumulation of 3T3-L1 Preadipocytes by Regulating the Expression of Lipogenic Genes and Adipokines.Frontiers in pharmacology · 2021Article
- Isolation and characterization of twoThe Journal of biological chemistry · 2020Article
- Liensinine inhibited gastric cancer cell growth through ROS generation and the PI3K/AKT pathway.Journal of Cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Once breast cancer cells grow aggressively and become lodged in the skeleton through migration and invasion, they interact with bone microenvironment and accelerate much more tumor growth and bone destruction. We investigated whether liensinine and nuciferine, major active components in
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.